Published in Hum Pathol on February 01, 2004
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology (2014) 2.23
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology (2013) 2.04
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol (2011) 1.72
MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res (2010) 1.56
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Hepatocellular ballooning in NASH. J Hepatol (2010) 1.48
Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol (2011) 1.48
Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol (2011) 1.12
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch (2011) 1.07
Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology (2014) 1.02
Intermediate filament cytoskeleton of the liver in health and disease. Histochem Cell Biol (2008) 0.99
Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology (2008) 0.97
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging (2011) 0.92
[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe (2010) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res (2011) 0.86
Non-alcoholic fatty liver disease and diabetes. Metabolism (2016) 0.82
Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD. Diabetes (2016) 0.81
Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol (N Y) (2006) 0.78
Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol (2011) 0.77
Effect of Sinai san decoction on the development of non-alcoholic steatohepatitis in rats. World J Gastroenterol (2005) 0.76
Serum transforming growth factor beta 3 predicts future development of nonalcoholic fatty liver disease. Int J Clin Exp Med (2015) 0.76
Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) (2014) 0.75
Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis (2015) 0.75
Effect of gadolinium on hepatic fat quantification using multi-echo reconstruction technique with T2* correction and estimation. Eur Radiol (2015) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Alcoholic liver disease. Hepatology (2010) 5.04
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut (2010) 2.46
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis (2007) 2.41
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol (2012) 2.11
Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci (2012) 2.11
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology (2005) 2.07
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Health-related quality of life in patients with chronic hepatitis B. Liver Int (2007) 1.90
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (2011) 1.81
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
MELD fails to measure quality of life in liver transplant candidates. Liver Transpl (2005) 1.79
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int (2008) 1.74
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med (2008) 1.72
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog (2006) 1.66
Non-invasive markers for hepatic fibrosis. BMC Gastroenterol (2011) 1.65
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology (2005) 1.63
Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation (2006) 1.61
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg (2005) 1.52
A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health (2009) 1.50
When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med (2010) 1.48
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol (2007) 1.46
Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology (2006) 1.44
In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol (2012) 1.40
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation (2005) 1.40
Resource utilization and survival among Medicare patients with advanced liver disease. Dig Dis Sci (2014) 1.40
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity? J Clin Endocrinol Metab (2004) 1.38
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol (2002) 1.34
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28